JPRN-jRCT2080225317已完成2 期
A Randomized, Double-blind, Cross-over Study of S-600918 in Participants with Sleep Apnea Syndrome
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 33
研究概览
简要总结
o obvious improvement in the primary endpoint of the change in AHI at Day 7 from baseline was found after administration of S-600918 300 mg compared with placebo, and the difference between the study drugs was not statistically significant. S-600918 was generally safe and well tolerated at a once daily dose of 300 mg for 7 days.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 70age old（—）
- 性别
- All
入选标准
- •Key Inclusion Criteria:
- •- Participants diagnosed with sleep apnea syndrome or suspected sleep apnea based on the International Classification of Sleep Disorders, Third Edition (ICSD-3).
排除标准
- •Key Exclusion Criteria:
- •- Participants with a clinically significant active respiratory disease.
- •- Participants with obvious morphological abnormalities of the upper respiratory tract, micrognathia, or developmental failure of the mandible.
研究者
相似试验
已完成
1 期
Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and OlderHealthy SubjectsNCT03008447Eisai Inc.60
已完成
3 期
Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSDJPRN-jRCT2080222347Chugai Pharmaceutical Co., Ltd.85
已完成
2 期
A randomized, double-blind, split-face study of topical silymarin versus 2% hydroquinone cream in melasmaMelasmaMelasma, Silymarin, Hydroquinone, SilibininTCTR20210729003/A23
已完成
不适用
Prospective clinical trial to evaluate efficacy, safety and usability of nanoemulsion cyclosporin 0.05%, emulsion cyclosporin 0.05% and diquafosol 3% in dry eye patientsDiseases of the eye and adnexaKCT0002180The Catholic University of Korea, Yeouido St. Mary's Hospital227
已完成
2 期
A Study of Brexpiprazole in Patients With Major Depressive DisorderMajor depressive disorderJPRN-jRCT2080223986Otsuka Pharmaceutical Co., Ltd.740